Your browser doesn't support javascript.
loading
The Development of Ecchymosis after Administration of Convalescent Serum in a Patient with COVID-19 Associated with Thrombocytosis.
Khot, Rajashree; Kumbhalkar, Sunita D; Juneja, Richa; Joshi, Prashant P.
Afiliação
  • Khot R; Department of General Medicine, AIIMS, Nagpur, Maharashtra, India.
  • Kumbhalkar SD; Department of General Medicine, AIIMS, Nagpur, Maharashtra, India.
  • Juneja R; Department of Pathology (Haematology), AIIMS, Nagpur, Maharashtra, India.
  • Joshi PP; Department of General Medicine, AIIMS, Nagpur, Maharashtra, India.
Eur J Case Rep Intern Med ; 8(9): 002782, 2021.
Article em En | MEDLINE | ID: mdl-34671574
ABSTRACT
COVID-19 can have an unpredictable and severe course, leading to many hypotheses regarding its pathophysiology and clinical manifestations. Haematological manifestations are a significant predictor of disease severity. The most common observation is lymphopenia with an increased neutrophillymphocyte ratio. Platelets have been implicated in thrombogenic events, but the most frequently reported abnormality is mild thrombocytopenia. Here we present an interesting case of a patient with moderate COVID-19 who presented with cutaneous ecchymoses and thrombocytosis, and discuss this paradox. LEARNING POINTS Bleeding manifestations such as ecchymoses can occur as an idiosyncratic reaction to the administration of convalescent plasma therapy in COVID-19.Thrombocytosis can occur in COVID-19 and could be a contributory factor to disease vasculopathy.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article